Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

amgen biopharmaceuticals malaysia sdn bhd - romosozumab -

Israel - engelsk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

Israel - engelsk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - concentrate for solution for infusion - risankizumab 60 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

USA - engelsk - NLM (National Library of Medicine)

stelis biopharma limited - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see clinical studies (14.1)], heart [see clinical studies (14.2)] or liver transplants [see clinical studies (14.3)] , in combination with other immunosuppressants. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil for injection is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. mycophenolate mofetil is contraindicated in patients who are allergic to polysorbate 80 (tween). pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycop

USA - engelsk - NLM (National Library of Medicine)

armas pharmaceuticals inc - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see clinical studies (14.1)], heart [see clinical studies (14.2)] or liver transplants [see clinical studies (14.3)] , in combination with other immunosuppressants. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil for injection is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. mycophenolate mofetil is contraindicated in patients who are allergic to polysorbate 80 (tween). pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. to report a pregnancy or obtain information about the re

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - 47186 - haematological concentrate system applicator - simultaneous application of biological components of fibrin sealants onto surgical tissue by dripping or spraying.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - 47860 - surgical air pipeline regulator - regulates the pressure of gas obtained from either a wall outlet or a pressurized container to the recommended range. allows gas to be supplied to the applicator device at the recommended pressure allowing sealant to be sprayed, when the foot pedal is depressed.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - interferon beta-1a 30ug;   - injection with diluent - 30 mcg - active: interferon beta-1a 30ug   excipient: albumin dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).

Israel - engelsk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules - paricalcitol 1 mcg - paricalcitol - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Israel - engelsk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - carbidopa as monohydrate; levodopa - gel - levodopa 20 mg/ml; carbidopa as monohydrate 5 mg/ml - levodopa - levodopa - treatment of advanced levodopa-responsive parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of parkinson medicinal products have not given satisfactory results.